By Nanomerics
Gene Delivery · Nose-to-Brain Non-viral, intranasal siRNA and pDNA delivery to the brain. METfect nanoparticles are deposited in the olfactory region and transported directly to multiple brain regions via the olfactory and perivascular pathways — bypassing the blood-brain barrier without injection. - 50–55% CNS gene knockdown in vivo - Self-administered nasal powder · re-dosable - siRNA, pDNA, and gene powder compatible A non-viral, non-invasive gene delivery platform that encapsulates siRNA and pDNA in biodegradable polymeric nanoparticles for direct CNS access via the olfactory pathway. 50–55% Gene Knockdown — siRNA · Mouse Cerebral Cortex 1,830× Lower Cytotoxicity vs Lipofectamine 2000 Non-invasive — Self-Administered — Repeatable Dosing Nose-to-Brain Delivery: Intranasal administration deposits METfect nanoparticles in the olfactory region, bypassing the blood-brain barrier via olfactory and perivascular pathways to achieve broad CNS distribution. Payload Flexibility: A single platform compatible with siRNA, pDNA, and gene powder formats. Spray-dried nano-in-micro particles provide room-temperature stability for 3+ months, enabling scalable manufacturing. Re-dosable Gene Medicine: Unlike viral vectors limited by immunogenicity and a single-administration paradigm, METfect nanoparticles are re-dosable — enabling chronic disease management with a patient-friendly nasal spray. Gene Powder — First Published Polymeric Gene Dry Powder: Spray-dried METfect nano-in-micro gene powder provides room-temperature stability for 3+ months — enabling scalable manufacturing and cold-chain-free distribution for global access.
